Advertisement

Topics

Mirvaso (brimonidine)

21:06 EDT 21st September 2017 | BioPortfolio

MIRVASO® (BRIMONIDINE) TOPICAL GEL, 0.33%* IS THE FIRST & ONLY FDA-APPROVED TREATMENT DEVELOPED AND INDICATED FOR PERSISTENT FACIAL REDNESS OF ROSACEA

Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.

What Is Rosacea?

Rosacea is a common skin condition that affects an estimated 16 million Americans. Facial redness is the most widely experienced rosacea symptom, and, according to the National Rosacea Society, may be the only symptom many people will experience.

Rosacea is a common vascular and inflammatory facial skin condition. People with fair skin over age 30 are more likely to get rosacea, but it can affect people of any age, from any background.

The facial redness of rosacea, also called erythema (err-uh-thee-ma), is a common rosacea symptom—and may be the only symptom for some people. A 2012 Gallup survey asked 510 people with rosacea which symptoms they were currently experiencing and found that facial redness was by far the most common.

Manufacturer: Galderma Laboratories

Website - http://www.mirvaso.com/

Quick Search
Advertisement
 

review and buy Mirvaso (brimonidine) market research data and corporate reports here